IL229419B - Thermostable vaccine compositions and methods of preparing same - Google Patents

Thermostable vaccine compositions and methods of preparing same

Info

Publication number
IL229419B
IL229419B IL229419A IL22941913A IL229419B IL 229419 B IL229419 B IL 229419B IL 229419 A IL229419 A IL 229419A IL 22941913 A IL22941913 A IL 22941913A IL 229419 B IL229419 B IL 229419B
Authority
IL
Israel
Prior art keywords
methods
vaccine compositions
preparing same
thermostable vaccine
thermostable
Prior art date
Application number
IL229419A
Other languages
Hebrew (he)
Other versions
IL229419A0 (en
Inventor
N Brey Robert
Kimberly Hassett
Pradyot Nandi
John Carpenter
Theodore Randolph
Original Assignee
N Brey Robert
Kimberly Hassett
Pradyot Nandi
John Carpenter
Theodore Randolph
Univ Colorado Regents
Soligenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Brey Robert, Kimberly Hassett, Pradyot Nandi, John Carpenter, Theodore Randolph, Univ Colorado Regents, Soligenix Inc filed Critical N Brey Robert
Publication of IL229419A0 publication Critical patent/IL229419A0/en
Publication of IL229419B publication Critical patent/IL229419B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL229419A 2011-05-17 2013-11-13 Thermostable vaccine compositions and methods of preparing same IL229419B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487206P 2011-05-17 2011-05-17
PCT/US2012/038457 WO2012158978A1 (en) 2011-05-17 2012-05-17 Thermostable vaccine compositions and methods of preparing same

Publications (2)

Publication Number Publication Date
IL229419A0 IL229419A0 (en) 2014-01-30
IL229419B true IL229419B (en) 2018-12-31

Family

ID=47177354

Family Applications (1)

Application Number Title Priority Date Filing Date
IL229419A IL229419B (en) 2011-05-17 2013-11-13 Thermostable vaccine compositions and methods of preparing same

Country Status (9)

Country Link
EP (2) EP3449938A1 (en)
JP (2) JP6110845B2 (en)
KR (2) KR20140106389A (en)
CN (2) CN107625958A (en)
AU (4) AU2012255132B2 (en)
CA (1) CA2836273C (en)
DK (1) DK2709657T3 (en)
IL (1) IL229419B (en)
WO (1) WO2012158978A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103083663B (en) * 2013-02-04 2014-12-10 江苏省农业科学院 Immunity enhancing agent, inactivated vaccine, and preparation method thereof
ES2897659T3 (en) 2013-09-03 2022-03-02 Georgia Tech Res Inst Thermally stable vaccine formulations, processes and microneedles including vaccine formulations
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EP3086780A4 (en) * 2013-12-27 2017-08-09 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
KR102411781B1 (en) * 2013-12-31 2022-06-22 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Single vial vaccine formulations
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
JP6707469B2 (en) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド Lyophilized formulation of Tat-NR2B9c containing acetylated scavenger
JP6674944B2 (en) * 2014-07-18 2020-04-01 エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドＭｓｄ Ｗｅｌｌｃｏｍｅ Ｔｒｕｓｔ Ｈｉｌｌｅｍａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｐｖｔ．Ｌｔｄ． Improved thermostable spray-dried rotavirus vaccine formulation and method for producing the same
CN104383528B (en) * 2014-10-24 2016-08-24 江苏省农业科学院 Pig epidemic diarrhea inactivated vaccine and preparation method thereof
SG11201803594TA (en) 2015-11-06 2018-05-30 Adjuvance Technologies Inc Triterpene saponin analogues
TW201722472A (en) * 2015-11-27 2017-07-01 Nitto Denko Corp Vaccine pharmaceutical composition for oral administration and method for manufacturing vaccine pharmaceutical composition for oral administration
US10722570B2 (en) * 2015-11-27 2020-07-28 Nitto Denko Corporation Dried influenza vaccine preparation and method for producing dried influenza vaccine preparation
US11160854B2 (en) 2016-07-11 2021-11-02 Limited Liability Company “Cancernet” Immunostimulatory preparation exhibiting antitumor activity
CN106215184A (en) * 2016-08-04 2016-12-14 肇庆大华农生物药品有限公司 A kind of preparation method of H7 hypotype recombinant fowl influenza virus live vector vaccine seed culture of viruses
KR20240023684A (en) 2016-09-13 2024-02-22 알레간 인코포레이티드 Stabilized non-protein clostridial toxin compositions
WO2018080253A1 (en) * 2016-10-31 2018-05-03 아이진 주식회사 Immunity enhancing composition including immune response regulator and cationic liposome, and use of same
US20180168196A1 (en) 2016-12-15 2018-06-21 Nestec Sa Compositions and methods that modulate bacteria in a companion animal
US20200325020A1 (en) * 2017-10-25 2020-10-15 Merck Sharp & Dohme Corp. Adjuvanted vaccines
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
GB2599572B (en) 2019-05-20 2023-09-20 Soligenix Inc Compositions and methods of manufacturing trivalent filovirus vaccines
CN111671894B (en) * 2020-06-29 2022-08-23 四川大学 Vaccine delivery system based on aluminum adjuvant and preparation method thereof
WO2022020815A1 (en) * 2020-07-24 2022-01-27 Soligenix, Inc. Antibody/adjuvant compositions and methods of immune response generation against coronaviruses
EP4323377A1 (en) * 2021-04-14 2024-02-21 Adjuvance Technologies, Inc. Vaccines
CN114931632A (en) * 2022-06-06 2022-08-23 苏州尔生生物医药有限公司 Cancer vaccine based on antigen presenting cell membrane component and preparation method and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033488A1 (en) * 1994-06-02 1995-12-14 Quadrant Holdings Cambridge Limited Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
EP0831790B1 (en) * 1995-06-07 2003-05-07 Elan Drug Delivery Limited Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
US6592872B1 (en) * 1996-09-17 2003-07-15 The United States Of America As Represented By The Department Of Health And Human Services Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
US7037510B2 (en) * 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
AU3526700A (en) * 1999-03-12 2000-09-28 U.S. Army Medical Research Institute Of Infectious Diseases Deglycosylated ricin toxin a-chain vaccine
KR101441358B1 (en) * 2003-05-14 2014-09-24 이뮤노젠 아이엔씨 Drug Conjugate Composition
BRPI0616879A2 (en) * 2005-10-04 2011-07-05 Alk Abello As solid vaccine formulation
US20080226729A1 (en) * 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
WO2008118691A2 (en) 2007-03-22 2008-10-02 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition

Also Published As

Publication number Publication date
CA2836273A1 (en) 2012-11-22
IL229419A0 (en) 2014-01-30
JP2014516967A (en) 2014-07-17
KR102374576B1 (en) 2022-03-15
AU2020200335A1 (en) 2020-02-06
EP3449938A1 (en) 2019-03-06
AU2017218989A1 (en) 2017-09-07
WO2012158978A1 (en) 2012-11-22
KR20140106389A (en) 2014-09-03
EP2709657B1 (en) 2018-10-24
AU2012255132B2 (en) 2017-05-25
AU2017218989B2 (en) 2019-10-31
CA2836273C (en) 2019-01-15
AU2023237223A1 (en) 2023-10-26
EP2709657A4 (en) 2015-02-18
DK2709657T3 (en) 2019-01-14
EP2709657A1 (en) 2014-03-26
CN107625958A (en) 2018-01-26
AU2012255132A1 (en) 2013-12-19
KR20200089690A (en) 2020-07-27
CN103781491A (en) 2014-05-07
JP6110845B2 (en) 2017-04-05
NZ618319A (en) 2015-11-27
JP2017081928A (en) 2017-05-18

Similar Documents

Publication Publication Date Title
IL229419A0 (en) Thermostable vaccine compositions and methods of preparing same
HK1207001A1 (en) Immunostimulatory compositions and methods of use thereof
HK1215785A1 (en) Controlled release compositions and methods of using
EP2836224A4 (en) Compositions of microbiota and methods related thereto
EP2675471A4 (en) Hsa-related compositions and methods of use
ZA201402734B (en) Collector compositions and methods of using the same
SG11201501499SA (en) Multi-functional compositions and methods of use
HK1199739A1 (en) Algal lipid compositions and methods of preparing and utilizing the same
PL2739293T3 (en) Methods and compositions for production of vaccina virus
IL230855A0 (en) Cabazitaxel formulations and methods of preparing thereof
EP2731617A4 (en) Lipid-containing psa compositions, methods of isolation and methods of use thereof
EP2780114A4 (en) Eggshell powder compositions and methods of producing eggshell powder compositions
GB201200458D0 (en) Methods of preparing cells and compositions
EP2897639A4 (en) Improved vaccine compositions and methods of use
EP2704688A4 (en) Cochleate compositions and methods of making and using same
EP2825196A4 (en) Adjuvant and vaccine compositions
EP2718331A4 (en) N,n,n-trialkylpolymers, methods of their preparation and uses thereof
EP2766375A4 (en) Preparation of novel fluorocompounds, methods of preparation and compositions made therefrom
EP2755668A4 (en) Hyr1-derived compositions and methods of treatment using same
IL231505B (en) Pharmaceutical composition and method of preparing same
EP2725923A4 (en) Emulsifier compositions and methods of using such emulsifier compositions
EP2678361A4 (en) Compositions with enhanced immunogenicity and/or reduced reactogenicity and methods of use
EP2870238A4 (en) Compositions and methods related to viral vaccines
EP2742139A4 (en) Immunogenic compositions and methods therefor
HK1216891A1 (en) Bryoid compositions, methods of making and use thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed